Phase 1 study of EVQ-218
Latest Information Update: 01 Oct 2024
At a glance
- Drugs EVQ 218 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- 01 Oct 2024 New trial record
- 26 Sep 2024 According to an EVOQ Bio media release, The company recently completed a successful Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration and is confidently advancing toward Phase I clinical trials.